Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å evaluere behandlingsresultatene ved subkutan anifrolumab hos pasienter med systemisk lupus erythematosus som ikke har fått immunundertrykkende behandling eller biologisk behandling tidligere (SUNFLOWER)

9. november 2026 oppdatert av: AstraZeneca

Multinasjonal, intervensjonell, 52-ukers, åpen, énarmsstudie for å evaluere behandlingsresultatene av Anifrolumab 120 mg subkutant én gang i uken hos immunsuppresiv-naive og biologisk-naive pasienter med systemisk lupus erythematosus (SUNFLOWER)

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment.

Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

In this study, approximately 275 participants will be enrolled and the study duration will be up to approximately 69 weeks, including: A Screening Period lasting up to 35 days and A 52-week treatment period. Also, participants not continuing treatment with any preparation of anifrolumab after Week 52 will have additional safety follow up 12 weeks after last dose of anifrolumab. Anifrolumab will be administered SC via an aPFS during the 52-week Study.

The study population will comprise participants taking antimalarial with or without GCs (there is a recruitment cap of 50% of patients not on GC at baseline) who are IS-naïve and biologic-naïve and are not meeting LLDAS criteria, described by the following cohorts:

  • Clinical SLEDAI 2K ≥4 points regardless of GC dose and disease duration.
  • Clinical SLEDAI-2K < 4 with GC ≥ 7.5 mg/day for > 5 weeks. After receiving the first dose of anifrolumab (week 0), the participant is allowed to increase the GC dose up until week 4, based on the investigator's recommendation. Between week 5 and week 40, participants taking >5 mg/day GC dose at study entry will attempt a protocolized taper to 5 mg/day over 12 weeks. Participants achieving DORIS remission for 2 consecutive visits will attempt complete withdrawal of GC following a 12-week tapering regimen. Starting week 41 until the end of the study (week 52), there will be no further reduction of GC dose.

Studietype

Intervensjonell

Registrering (Antatt)

245

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2T 5C7
        • Har ikke rekruttert ennå
        • Research Site
    • British Columbia
      • Richmond, British Columbia, Canada, V6Z 1Y6
        • Har ikke rekruttert ennå
        • Research Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3A 1M4
        • Har ikke rekruttert ennå
        • Research Site
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • Har ikke rekruttert ennå
        • Research Site
      • Toronto, Ontario, Canada, M5T 2S8
        • Har ikke rekruttert ennå
        • Research Site
  • Forente stater
    • Alabama
      • Anniston, Alabama, Forente stater, 36207
        • Tilbaketrukket
        • Research Site
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • Research Site
    • Arizona
      • Phoenix, Arizona, Forente stater, 85032
        • Rekruttering
        • Research Site
      • Tucson, Arizona, Forente stater, 85748
        • Rekruttering
        • Research Site
    • California
      • Fontana, California, Forente stater, 92335
        • Har ikke rekruttert ennå
        • Research Site
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • Research Site
      • La Palma, California, Forente stater, 90623
        • Rekruttering
        • Research Site
      • Menifee, California, Forente stater, 92586
        • Rekruttering
        • Research Site
      • San Leandro, California, Forente stater, 94578
        • Rekruttering
        • Research Site
      • Temecula, California, Forente stater, 92592
        • Rekruttering
        • Research Site
    • Florida
      • Brandon, Florida, Forente stater, 33511
        • Har ikke rekruttert ennå
        • Research Site
      • Miami, Florida, Forente stater, 33136
        • Har ikke rekruttert ennå
        • Research Site
      • Miami, Florida, Forente stater, 33145
        • Rekruttering
        • Research Site
      • Miami, Florida, Forente stater, 33180
        • Suspendert
        • Research Site
      • St. Petersburg, Florida, Forente stater, 33705
        • Har ikke rekruttert ennå
        • Research Site
    • Illinois
      • Willowbrook, Illinois, Forente stater, 60527
        • Rekruttering
        • Research Site
    • Indiana
      • New Albany, Indiana, Forente stater, 47150
        • Rekruttering
        • Research Site
    • Louisiana
      • Lake Charles, Louisiana, Forente stater, 70605
        • Rekruttering
        • Research Site
    • Maryland
      • Silver Spring, Maryland, Forente stater, 20904
        • Rekruttering
        • Research Site
    • Missouri
      • Kansas City, Missouri, Forente stater, 64151
        • Rekruttering
        • Research Site
    • New Jersey
      • West Long Branch, New Jersey, Forente stater, 07764
        • Rekruttering
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Har ikke rekruttert ennå
        • Research Site
      • Oklahoma City, Oklahoma, Forente stater, 73116
        • Rekruttering
        • Research Site
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38119
        • Rekruttering
        • Research Site
      • Memphis, Tennessee, Forente stater, 38104
        • Har ikke rekruttert ennå
        • Research Site
    • Texas
      • Austin, Texas, Forente stater, 78745
        • Har ikke rekruttert ennå
        • Research Site
      • Baytown, Texas, Forente stater, 77521
        • Rekruttering
        • Research Site
      • Colleyville, Texas, Forente stater, 76034
        • Rekruttering
        • Research Site
      • Edinburg, Texas, Forente stater, 78550
        • Rekruttering
        • Research Site
      • Houston, Texas, Forente stater, 77054
        • Rekruttering
        • Research Site
      • Sugar Land, Texas, Forente stater, 77479
        • Rekruttering
        • Research Site
    • Washington
      • Spokane, Washington, Forente stater, 99204
        • Rekruttering
        • Research Site
  • Frankrike
      • Clermont-Ferrand, Frankrike, 63000
        • Rekruttering
        • Research Site
      • Lyon, Frankrike, 69437
        • Rekruttering
        • Research Site
      • Marseille, Frankrike, 13385
        • Rekruttering
        • Research Site
      • Paris, Frankrike, 75012
        • Rekruttering
        • Research Site
      • Paris, Frankrike, 75013
        • Rekruttering
        • Research Site
      • Pessac, Frankrike, 33604
        • Rekruttering
        • Research Site
      • Saint-Denis, Frankrike, 97405
        • Har ikke rekruttert ennå
        • Research Site
      • Saint-Pierre, Frankrike, 97448
        • Har ikke rekruttert ennå
        • Research Site
      • Toulon, Frankrike, 83800, Cedex
        • Rekruttering
        • Research Site
      • Tours, Frankrike, 37044
        • Rekruttering
        • Research Site
      • Vandœuvre-lès-Nancy, Frankrike, 54511
        • Har ikke rekruttert ennå
        • Research Site
  • Italia
      • Brescia, Italia, 25123
        • Har ikke rekruttert ennå
        • Research Site
      • Catania, Italia, 95123
        • Har ikke rekruttert ennå
        • Research Site
      • Ferrara, Italia, 44121
        • Rekruttering
        • Research Site
      • Florence, Italia, 50141
        • Har ikke rekruttert ennå
        • Research Site
      • Milan, Italia, 20122
        • Rekruttering
        • Research Site
      • Milan, Italia, 20122
        • Suspendert
        • Research Site
      • Padova, Italia, 35128
        • Har ikke rekruttert ennå
        • Research Site
      • Pisa, Italia, 56124
        • Har ikke rekruttert ennå
        • Research Site
      • Roma, Italia, 00161
        • Har ikke rekruttert ennå
        • Research Site
      • Roma, Italia, 00168
        • Suspendert
        • Research Site
      • Rozzano, Italia, 20089
        • Har ikke rekruttert ennå
        • Research Site
      • Udine, Italia, 33100
        • Har ikke rekruttert ennå
        • Research Site
  • Mexico
      • Culiacán, Mexico, 80000
        • Har ikke rekruttert ennå
        • Research Site
      • Durango, Mexico, 34080
        • Har ikke rekruttert ennå
        • Research Site
      • Guadalajara, Mexico, 44160
        • Har ikke rekruttert ennå
        • Research Site
      • Guadalajara, Mexico, 44650
        • Har ikke rekruttert ennå
        • Research Site
      • Guadalajara, Mexico, 44690
        • Suspendert
        • Research Site
      • Mérida, Mexico, 97133
        • Har ikke rekruttert ennå
        • Research Site
      • México, Mexico, 14080
        • Har ikke rekruttert ennå
        • Research Site
      • México, Mexico, 03100
        • Har ikke rekruttert ennå
        • Research Site
  • Polen
      • Bydgoszcz, Polen, 85-065
        • Rekruttering
        • Research Site
      • Częstochowa, Polen, 42-217
        • Rekruttering
        • Research Site
      • Katowice, Polen, 40-611
        • Rekruttering
        • Research Site
      • Krakow, Polen, 30-688
        • Har ikke rekruttert ennå
        • Research Site
      • Lodz, Polen, 90-368
        • Rekruttering
        • Research Site
      • Lublin, Polen, 20-607
        • Rekruttering
        • Research Site
      • Nadarzyn, Polen, 05-830
        • Rekruttering
        • Research Site
      • Nowa Sól, Polen, 67-100
        • Rekruttering
        • Research Site
      • Poznan, Polen, 60-693
        • Har ikke rekruttert ennå
        • Research Site
      • Poznan, Polen, 60-681
        • Har ikke rekruttert ennå
        • Research Site
      • Poznan, Polen, 61-397
        • Rekruttering
        • Research Site
      • Warsaw, Polen, 02-637
        • Har ikke rekruttert ennå
        • Research Site
      • Warsaw, Polen, 01-691
        • Rekruttering
        • Research Site
      • Warsaw, Polen, 05-077
        • Rekruttering
        • Research Site
      • Wroclaw, Polen, 53-673
        • Rekruttering
        • Research Site
  • Spania
      • Barcelona, Spania, 08035
        • Rekruttering
        • Research Site
      • Barcelona, Spania, 08036
        • Rekruttering
        • Research Site
      • Córdoba, Spania, 14004
        • Suspendert
        • Research Site
      • Galdakao, Spania, 48960
        • Rekruttering
        • Research Site
      • Madrid, Spania, 28034
        • Rekruttering
        • Research Site
      • Madrid, Spania, 28046
        • Rekruttering
        • Research Site
      • Madrid, Spania, 28702
        • Rekruttering
        • Research Site
      • Sabadell, Spania, 08208
        • Har ikke rekruttert ennå
        • Research Site
      • Santander, Spania, 39008
        • Har ikke rekruttert ennå
        • Research Site
      • Seville, Spania, 41014
        • Har ikke rekruttert ennå
        • Research Site
      • Valencia, Spania, 46026
        • Har ikke rekruttert ennå
        • Research Site
  • Taiwan
      • Kaohsiung City, Taiwan, 833
        • Har ikke rekruttert ennå
        • Research Site
      • Kaohsiung City, Taiwan, 813414
        • Har ikke rekruttert ennå
        • Research Site
      • New Taipei City, Taiwan, 23561
        • Har ikke rekruttert ennå
        • Research Site
      • Taichung, Taiwan, 40705
        • Har ikke rekruttert ennå
        • Research Site
      • Taichung, Taiwan, 40447
        • Har ikke rekruttert ennå
        • Research Site
      • Tainan, Taiwan, 70403
        • Har ikke rekruttert ennå
        • Research Site
      • Tainan County, Taiwan, 71044
        • Har ikke rekruttert ennå
        • Research Site
      • Taipei, Taiwan, 100
        • Har ikke rekruttert ennå
        • Research Site
      • Taoyuan, Taiwan, 33305
        • Har ikke rekruttert ennå
        • Research Site
      • Zhubei, Taiwan, 302
        • Har ikke rekruttert ennå
        • Research Site
  • Tyskland
      • Bad Abbach, Tyskland, 93077
        • Tilbaketrukket
        • Research Site
      • Hamburg, Tyskland, 22763
        • Har ikke rekruttert ennå
        • Research Site
      • Mainz, Tyskland, 55131
        • Har ikke rekruttert ennå
        • Research Site
      • München, Tyskland, 80336
        • Har ikke rekruttert ennå
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Males or females aged 18 to 70 years of age.

  2. Participants who have a diagnosis of SLE confirmed by a rheumatologist.

  3. ANA-positive per the Central Lab at screening:

    (a) ANA (b) Anti-dsDNA (c) Anti-Smith (anti-Sm)

  4. Must be on the standard therapy regimen: antimalarials with or without OCSs

  5. Must have at screening and baseline:

    1. Clinical SLEDAI-2K ≥ 4 points OR
    2. Clinical SLEDAI-2K < 4 with GC dose ≥ 7.5 mg/day (prednisone equivalent)

  6. Should have no evidence of current active infection, (e.g., pneumonia, tuberculosis [TB]) or previous TB

  7. Should have no evidence of malignancy; and clinically significant abnormalities (unless due to SLE).

  8. No medical history or signs or symptoms of active TB prior to or during Screening.

  9. Body weight ≥ 40.0 kg

  10. Negative pregnancy test for females during screening

  11. Normal HPV test result within 2 years prior to Week 0 (Day 1).

  12. Willing and able to participate in all required study evaluations and procedures including completion of PROs.

  13. Willing to not use any other forms of experimental treatment during the study.

Exclusion Criteria:

  1. Subjects with history of, or current diagnosis of, a clinically significant non-SLE related vasculitis syndrome.

  2. Subjects with antiphospholipid antibody syndrome on stable anticoagulant therapy at an effective dose (e.g., if on warfarin, an international normalized ratio [INR] target 2 to 3 or as appropriate for the clinical situation) are only allowed if this is not the sole or the predominant feature of their SLE.

  3. Subjects with a serious thrombotic event (e.g., pulmonary embolism stroke, deep vein thrombosis) or unexplained pregnancy loss within 1 year before the screening visit are excluded.

  4. Subjects with a history of catastrophic antiphospholipid syndrome or saddle embolism.

  5. Subjects with a history of 3 or more unexplained consecutive pregnancy losses.

  6. History or evidence of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months or recurrent suicidal behavior in the lifetime of the participant based on an assessment with the Columbia Suicide Severity Rating Scale (C SSRS) at Screening.

  7. Active severe or unstable neuropsychiatric SLE including, but not limited to aseptic meningitis, cerebral vasculitis, myelopathy, demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy), acute confusional state, impaired level of consciousness, psychosis, acute stroke or stroke syndrome, cranial neuropathy, status epilepticus, cerebellar ataxia, lupus headache and mononeuritis multiplex, where, protocol-specified standard therapy is insufficient.

  8. Active severe SLE-driven renal disease where, protocol-specified standard therapy is insufficient.

  9. Current diagnosis of, catastrophic antiphospholipid syndrome (APS).

  10. History of recurrent infection requiring hospitalization and IV antibiotics (e.g., 3 or more of the same type of infection over the previous 52 weeks).

  11. Known History of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection, or a positive result for HIV at Screening.

  12. Confirmed positive test for hepatitis B.

  13. Any clinical cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection that has not completely resolved within 12 weeks prior to signing the ICF.

  14. Opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of Week 0 (Day 1).

  15. Clinically significant chronic infection (e.g., osteomyelitis, bronchiectasis, etc.) within 8 weeks prior to signing the ICF (chronic nail infections are allowed).

  16. Severe HZ or recurrent HZ.

  17. Malignancy. History of cancer, apart from:

    (a) Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy ≥ 3 months prior to Week 0 (Day 1).

    (a) Cervical cancer in situ treated with apparent success with curative therapy ≥ 1 year prior to Week 0 (Day 1).

  18. Received any SLE-related therapies other than antimalarials and GCs.

  19. History of allergy or reaction to any component of the study intervention formulation or history of anaphylaxis to any human gamma globulin therapy.

  20. History of an anaphylactic reaction to human proteins or mAbs.

  21. Received any live or attenuated vaccine within 8 weeks prior to signing the ICF.

  22. Blood transfusion or receipt of blood products except albumin.

  23. Received more than 2 investigational products for the SLE since time of diagnosis.

  24. Received any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater.

  25. Concurrent enrollment in another clinical study with a study intervention.

  26. Subjects with any abnormal lab result as specified in the protocol.

  27. Subjects with other autoimmune diseases (e.g., multiple sclerosis, psoriasis, IBD, etc.).

  28. Subjects with SLE overlap syndromes such as scleroderma and mixed connective tissue disease.

  29. Subject with non-SLE concomitant illness, as determined by medical judgment, who is likely to require additional systemic glucocorticosteroid therapy during the study (e.g., asthma).

  30. Any condition would interfere with treatment outcomes of the study intervention or put participant at safety risk.

  31. Lactating, breastfeeding, or pregnant females or females who intend to become pregnant or begin breastfeeding anytime from initiation of Screening until 16 weeks following last dose of study intervention.

  32. Spontaneous or induced abortion, still or live birth, or pregnancy ≤ 4 weeks prior to signing the ICF.

  33. Current alcohol, drug or chemical abuse, or a history of such abuse within 1 year before Week 0 (Day 1).

  34. Major surgery within 8 weeks before signing the ICF or elective major surgery planned during the study period.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Anifrolumab

Participants will receive dose A of anifrolumab on X dosing schedule beginning on Day 1 for a maximum of 52 -week during the study
Legemiddel: Anifrolumab

Patients will receive Anifrolumab subcutaneous

Andre navn:
  • Saphnelo

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Attainment of DORIS remission
Tidsramme: At Week 52

Proportion of participants who are in DORIS remission at Week 52 will be assessed.

DORIS remission is defined as Clinical SLEDAI-2K (sum of all SLEDAI-2K items except for increased deoxyribonucleic acid [DNA] binding and low complement) = 0; PGA [0-3] < 0.5, prednisone 5 mg/day or less, and stable antimalarials, ISs, and biologics.
At Week 52

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To assess the attainment of low level disease activity
Tidsramme: At Week 28 and 52

Proportion of participants who are in LLDAS, or LLDAS-5 at Week 28 and 52 will be assessed.

Low level disease activity as measured by LLDAS and LLDAS 5

  • LLDAS criteria: SLEDAI 2K ≤ 4 without major organ involvement, no new disease activity, PGA ≤ 1 (0 - 3), prednisone 7.5 mg/day or less, and permitted use of the following medications: antimalarials, standard maintenance doses of ISs including biologics
  • LLDAS-5 criteria: SLEDAI-2K ≤ 4 without major organ involvement, no new disease activity, PGA ≤ 1 (0 - 3), prednisone 5.0 mg/day or less (this is modified LLDAS to include EULAR 2023 recommendations to lower daily maintenance GC ≤ 5.0 mg/day)
At Week 28 and 52
Time spent in DORIS remission, LLDAS or LLDAS-5
Tidsramme: At Week 52

Time spent in DORIS remission, LLDAS or LLDAS-5 for participants initiated on anifrolumab will be measured.
At Week 52
Sustaining DORIS remission, LLDAS or LLDAS-5
Tidsramme: All subsequent visits including 52 Week

The proportion of participants initiated on anifrolumab, sustaining DORIS remission, LLDAS or LLDAS-5 through to Week 52 will be measured.
All subsequent visits including 52 Week
Sustaining DORIS remission, LLDAS or LLDAS-5
Tidsramme: At 3 consecutive visits occurring every 4 weeks during the 52 Week study

The proportion of participants initiated on anifrolumab, sustaining DORIS remission, LLDAS or LLDAS-5 for three or more consecutive visits will be measured.

Consecutive visits' are defined as three back-to-back completed visits.
At 3 consecutive visits occurring every 4 weeks during the 52 Week study
Time to attain and sustain DORIS, or LLDAS, or LLDAS-5
Tidsramme: Through Week 52

The time to attain and sustain DORIS, or LLDAS, or LLDAS-5 will be analyzed.
Through Week 52
Daily GC dose
Tidsramme: At Week 40 and Week 52

The daily GC dose at Week 40 and 52 in participants initiated on anifrolumab alongside a systematic approach to GC tapering and to assess the maintenance of this GC reduction through Week 52 will be assessed.
At Week 40 and Week 52
Reduction in GC use
Tidsramme: From Week 4 to Week 40

The reduction in GC use from Week 4 to Week 40 in participants initiated on anifrolumab alongside a systematic approach to GC tapering will be assessed
From Week 4 to Week 40
Maintenance of reduction in GC dose
Tidsramme: During 52 Week

Maintenance of this percent reduction in GC dose through Week 52 will be assessed
During 52 Week
Cumulative GC dose
Tidsramme: Week 0 to Week 52

The cumulative GC dose from Week 0 to Week 52 in participants initiated on anifrolumab alongside a systematic approach to GC tapering will be assessed.
Week 0 to Week 52
Attainment of DORIS-0
Tidsramme: From baseline over 52 Weeks

Proportion of participants who attain DORIS-0 from baseline over 52 weeks. DORIS-0 is defined as DORIS criteria with prednisone 0 mg daily.
From baseline over 52 Weeks
Time to first moderate-to-severe flare
Tidsramme: Through Week 52

Time to first moderate-to-severe flare through to Week 52 assessed based on MFI. Moderate-to-severe flare is defined as any one criterion present in the moderate or severe flare categories within the MFI will be assessed.
Through Week 52
Change in active skin manifestations
Tidsramme: At Week 4, Week 16, and Week 52

The change in active skin manifestations of SLE measured by CLASI activity score in participants initiated on anifrolumab will be assessed.
At Week 4, Week 16, and Week 52
Change in joint activity
Tidsramme: At Week 28 and 52

The average change in number of active joints (swollen and tender joints) in participants initiated on anifrolumab compared to baseline will be assessed
At Week 28 and 52
Change in QoL and fatigue
Tidsramme: At 52 Week

Change in QoL and fatigue in participants initiated on anifrolumab will be assessed using FACIT-F.
At 52 Week
Adverse Events
Tidsramme: Up to 52 Weeks

Safety and tolerability of anifrolumab will be assessed.
Up to 52 Weeks
Change in QoL and fatigue
Tidsramme: At 52 Week

Change in QoL and fatigue in participants initiated on anifrolumab will be assessed using PROMIS Lupus.
At 52 Week

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

AstraZeneca

Samarbeidspartnere

ICON plc

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. april 2026

Primær fullføring (Antatt)

26. januar 2029

Studiet fullført (Antatt)

26. januar 2029

Datoer for studieregistrering

Først innsendt

2. februar 2026

Først innsendt som oppfylte QC-kriteriene

18. februar 2026

Først lagt ut (Faktiske)

24. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • D3461C00040

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere